T1	intervention 0 22	High-dose chemotherapy
T2	location 129 135	French
T3	eligibility 345 378	metastatic breast cancer patients
T5	control 326 341	conventional CT
T7	total-participants 405 407	61
T8	intervention-participants 584 586	32
T9	control-participants 616 618	29
T10	outcome 742 753	median TTPs
T11	iv-cont-median 778 779	6
T12	cv-cont-median 784 793	12 months
T13	outcome 866 878	relapse rate
T14	iv-bin-percent 882 887	86.2%
T15	cv-bin-percent 892 897	62.5%
T16	outcome 898 908	at 2 years
T17	iv-bin-percent 914 918	100%
T18	cv-bin-percent 923 928	81.3%
T19	outcome 929 939	at 5 years
T20	outcome 945 960	median OS times
T21	iv-cont-median 966 970	19.3
T22	cv-cont-median 975 986	44.1 months
T23	outcome 996 1003	OS rate
T24	iv-bin-percent 1007 1012	13.8%
T25	cv-bin-percent 1017 1022	36.8%
T26	outcome 1023 1033	at 5 years
T27	eligibility 408 461	patients with chemosensitive metastatic breast cancer
T6	outcome 668 685	complete response
T28	outcome 693 709	partial response
T29	outcome 722 736	stable disease
